On the morning of October 30, Ma Xin, a member of the Standing Committee of the Jiangsu Provincial Party Committee and Executive Vice Governor, visited Jiangsu Hansoh, a subsidiary of Hansoh Pharma. Accompanying him were Yang Xinchong, Secretary-General of the provincial government; Shen Jianrong, Director of the Jiangsu Development and Reform Commission; and Tang Libin, Director of the Jiangsu Securities Regulatory Bureau. Ma Shiguang, Secretary of the Lianyungang Municipal Party Committee, also participated in the visit. Lyu Aifeng, Executive Director of Hansoh Pharma, hosted the delegation and provided an overview of the company’s recent innovations and achievements.
During the visit, Ma Xin and his team conducted a thorough review of the company’s advancements in production, operations, and research and development. Lyu Aifeng highlighted that Hansoh Pharma leverages an internationally leading innovative technology platform supported by a global R&D team of over 1,700 members, efficiently advancing its robust R&D pipeline. Currently, more than 30 innovative drugs are in over 50 clinical trials, with several poised to be first-in-class (FIC) or best-in-class (BIC). The company has seven marketed innovative drugs, covering nine indications, that are included in the national medical insurance catalog. Alongside its independent research, Hansoh Pharma is actively pursuing global collaboration, having launched 11 collaborative projects and completed two ADC product out-licensing agreements. Notably, HS-20093 (B7-H3 ADC) has received breakthrough therapy designation from the FDA.
After reviewing the company’s progress, Ma Xin praised Hansoh Pharma for its ongoing commitment to increasing research and development investment, advancing key technological breakthroughs, and driving innovation. He encouraged the company to explore the frontiers of global biotechnology and expedite the development and transformation of innovative technologies and products to ensure that patients benefit from new and effective drugs.
Statements Hansoh Pharma does not endorse the use of any unapproved drugs or indications. The medical information in this release is for informational and news reporting purposes only and is not intended for advertising. It should not be used for healthcare or diagnosis.
